| Zacks Company Profile for Alnylam Pharmaceuticals, Inc. (ALNY : NSDQ) |
|
|
| |
| • Company Description |
| Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
Number of Employees: 2,230 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $322.64 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 810,584 shares |
| Shares Outstanding: 130.39 (millions) |
| Market Capitalization: $42,068.52 (millions) |
| Beta: 0.23 |
| 52 Week High: $333.70 |
| 52 Week Low: $205.87 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
5.90% |
1.93% |
| 12 Week |
37.55% |
15.70% |
| Year To Date |
37.11% |
28.41% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
675 WEST KENDALL STREET HENRI A. TERMEER SQUARE
-
CAMBRIDGE,MA 02142
USA |
ph: 617-551-8200
fax: 617-551-8101 |
investors@alnylam.com |
http://www.alnylam.com |
|
|
| |
| • General Corporate Information |
Officers
Yvonne L. Greenstreet - Chief Executive Officer and Director
Jeffrey V. Poulton - Executive Vice President; Chief Financial Officer
Dennis A. Ausiello - Director
Carolyn R. Bertozzi - Director
Michael W. Bonney - Director
|
|
Peer Information
Alnylam Pharmaceuticals, Inc. (CORR.)
Alnylam Pharmaceuticals, Inc. (RSPI)
Alnylam Pharmaceuticals, Inc. (CGXP)
Alnylam Pharmaceuticals, Inc. (BGEN)
Alnylam Pharmaceuticals, Inc. (GTBP)
Alnylam Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 02043Q107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
|
|
Share - Related Items
Shares Outstanding: 130.39
Most Recent Split Date: (:1)
Beta: 0.23
Market Capitalization: $42,068.52 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.01 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.19 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 12.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/07/25 |
|
|
|
| |
